Corporate GovernanceMay 19, 2026, 04:08 PM
Silexion Therapeutics Amends 10-K for Internal Control Date Correction
AI Summary
Silexion Therapeutics Corp filed an amendment to its 10-K report to correct a typographical error in the date of its management's evaluation of internal control over financial reporting. The correct evaluation date is December 31, 2025, not December 31, 2024. The company's management, including the CEO and CFO, concluded that both disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2025.
Key Highlights
- Amended 10-K to correct a typographical error in the internal control over financial reporting evaluation date.
- The evaluation date was corrected from December 31, 2024, to December 31, 2025.
- Management concluded disclosure controls and procedures were effective as of December 31, 2025.
- Management concluded internal control over financial reporting was effective as of December 31, 2025.
- No material changes in internal control over financial reporting occurred during Q4 2025.
- The amendment also includes updated Exhibits 3.5 and 10.5.2, reflecting shareholder-approved matters.
Price Impact
More from SLXN